IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 28/06/2019 - Press release

    Possible marker of treatment resistance in HER2 breast cancer identified

    The ageing of NK lymphocytes circulating in the blood of patients with HER2-positive breast cancer is a marker that can predict the success or failure of monoclonal antibody therapies, which act on a specific factor in tumour cells.  This is the conclusion of a study led by researchers from the Hospital del Mar Medical Research Institute (IMIM) and the Pompeu Fabra University, and doctors from the Hospital del Mar, published in the journal Cancer Immunology Research. The study also involved staff from the Medical Oncology Service at Hospital Clínic in Valencia, the Pathological Anatomy Services at Hospital del Mar, Fundación Jiménez Díaz in Madrid, and the Immunogenetics Service at Puerta de Hierro University Institute, also in Madrid. It involved analysing blood samples from 66 patients, immunogenetic and functional studies of the NK lymphocytes of these patients, as well as analysing tumour biopsies. The ageing of these cells was measured by quantifying the NK lymphocytes in the blood that express the CD57 molecule. The results show that patients with high blood counts at the time of diagnosis are more likely to be resistant to chemotherapy and anti-HER2 antibody treatment. 

    Més informació "Possible marker of treatment resistance in HER2 breast cancer identified"

  • 04/04/2019 - Press release

    Paradigm shift in how bone fractures are avoided in HIV patients

    Doctors and researchers at Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) have shown, for the first time, that osteoporosis and bone fractures in HIV sufferers is caused by the body's response to the presence of the virus, in the form of inflammatory processes, and not only the antiretroviral treatment, as was previously believed. The study, published in the Journal of Antimicrobial Chemotherapy, used a bone-quality measuring technique designed in the United States in collaboration with staff from Hospital del Mar, together with a protocol developed by the same people, which shows that the risk of fractures is related to the inflammation caused by the chronic infection. This represents a change in how this problem is conceived, as well as how it is approached. The study involved staff from the Infectious Diseases and Internal Medicine services at Hospital del Mar, as well as members of the IMIM's Musculoskeletal Research Group. Dr. Todd T. Brown, from Johns Hopkins University, in the United States, also participated.

    Més informació "Paradigm shift in how bone fractures are avoided in HIV patients"

  • 19/11/2018 - Press release

    Gene vital for post-stroke recovery identified for the first time

    Having certain specific variants of the PATJ  gene predisposes to worse recovery from ischemic stroke. 7 out of 10 patients with these variants suffer severe sequelae three months after having a stroke, in other words, they are in a situation of dependence, compared to less than half of patients who do not present these variants. This is data from an international, multicentre study coordinated by researchers at the Hospital del Mar Medical Research Institute (IMIM) and doctors from the Hospital del Mar, published in the journal Circulation Research. This is the most important research carried out so far in the field of genetics and stroke prognosis, and the first published: it uses data from more than 2,000 patients and involves 12 centres from around the world. The study was carried out thanks to the help of the 2010 edition of La Marató de TV3.

    Més informació "Gene vital for post-stroke recovery identified for the first time"

  • 11/07/2017 - Press release

    Key immunological mechanism for regulating intestinal flora discovered

    Researchers at the Hospital del Mar Medical Research Institute (IMIM) have shown for the first time that immunoglobulin M, secreted by the human intestine, plays a key role in maintaining the diversity of intestinal flora by including and maintaining microorganisms that are beneficial to our health. These results have been published in the prestigious scientific journal Immunity. "We have discovered that, in addition to immunoglobulin A, (IgA), immunoglobulin M (IgM), secreted by the human intestine, interacts with the intestinal microbiota and actively participates in maintaining its diversity. In addition, we have demonstrated that this immunoglobulin is part of an immunological memory system through which our organism is able to recognise and adapt to its microbial environment", explain Giuliana Magri and Laura Comerma, researchers from the B Cell Biology research group at the IMIM and first authors of the article.

    Més informació "Key immunological mechanism for regulating intestinal flora discovered"

  • 28/07/2016 - Press release

    Hospital del Mar develops an innovative calculator to predict the risk of atrial fibrillation

    Cardiologists at the Hospital del Mar and researchers from the Hospital del Mar Medical Research Institute (IMIM) have developed a new tool that enables them to estimate atrial fibrillation risk using electrocardiogram indicators, basic clinical data, and parameters obtained through Holter monitors (small electronic devices that record and store a patient's electrocardiogram for 24 hours). The results of the project have just been published in the International Journal of Cardiology. Atrial fibrillation is a disease characterised by uncoordinated and disorganised atrial beats that produce a rapid and irregular heart rate. It is estimated that it affects between 1.5 and 2% of people in the developed world and the percentage increases with age.

    Més informació "Hospital del Mar develops an innovative calculator to predict the risk of atrial fibrillation"

  • 20/07/2016 - Press release

    A combination of therapies improves lung cancer treatment

    Lung cancer is the most deadly cancer in the world, causing more than one and a half million deaths a year. The most common subtype of lung cancer is adenocarcinoma. The presence of other underlying conditions, such as chronic obstructive pulmonary disease (COPD), which is also responsible for a high mortality rate in industrialised regions, increases the risk of developing it. Despite recent progress in therapeutic strategies for combatting this disease, the majority of patients who are diagnosed do not survive for more than five years. It is a cancer that can develop silently for many months and, in some cases, the symptoms can be confused with other diseases, such as the already-mentioned COPD. This is why it is usually diagnosed in very advanced stages. To all these impediments, it is necessary to add the difficulty of finding an appropriate treatment for each patient, since there is a high level of resistance to currently-used drugs. 

    Més informació "A combination of therapies improves lung cancer treatment"

  • 16/06/2016 - Press release

    When is the best time to have carotid stenosis surgery after a stroke?

    An international study led by the Neurology Service at Hospital del Mar and the Neurovascular research group at the Hospital del Mar Medical Research Institute (IMIM) has quantified the risk and developed predictors for ischemic stroke in patients with carotid artery stenosis. The results of the study, published in the journal Neurology, have confirmed that there is a high risk of recurrence in the first 14 days after the stroke, which is the recommended time for carotid revascularisation surgery. But since very urgent surgery entails a considerable surgical risk, it is necessary to determine the most appropriate time for undertaking this operation in the fourteen days following the stroke. The study provides a starting point and randomised trials are recommended to determine the benefits and safety of emergency revascularisation as opposed to subacute carotid revascularisation within 14 days after the onset of symptoms.

    Més informació "When is the best time to have carotid stenosis surgery after a stroke?"

  • 31/03/2016 - Press release

    Hospital del Mar and Vall d'Hebron take part in the biggest international genomic study into strokes

    The Hospital del Mar Medical Research Institute and the Vall d'Hebron Research Institute, in collaboration with the MútuaTerrassa Foundation, were the only Spanish research centres to participate in the largest study to date into genome association with ischaemic stroke, and which involved around 38,000 patients and 400,000 control subjects. The study, published recently in Lancet Neurology by two international consortia, has led to the identification of a gene implicated in atherothrombotic ischaemic stroke. The team of Dr. Jordi Jiménez-Conde, head of the Genetics Area within the Neurovascular Research Group at the IMIM and a neurologist at the Hospital del Mar, took part in the discovery phase of the study. This first part involved the analysis of nearly 900 samples from stroke patients and 1200 controls from the Hospital del Mar, this being the second-ranked centre internationally according number of cases.

    Més informació "Hospital del Mar and Vall d'Hebron take part in the biggest international genomic study into strokes"

  • 08/02/2016 - Press release

    New type 2 diabetes biomarker identified

    Researchers from the Hospital del Mar Medical Research Institute (IMIM) have found an epigenetic mechanism implicated in the regulation of blood sugar. The study, published in the journal Molecular Human Genetics, reveals that the methylation of the TXNIP gene is associated with diabetes mellitus type 2 and, in particular, average blood glucose levels. These results, replicated in two patient cohorts, could help to both identify patients at risk of developing diabetes and control treatment response, as well as generating possible future therapies for this disease, one of the major cardiovascular risk factors in the population. The work was coordinated by Carolina Soriano, from the Neurovascular research group at the IMIM, and Jordi Jiménez Conde, from the same group and a neurologist at the Hospital del Mar, in collaboration with the IMIM's Cardiovascular Epidemiology and Genetics group. 

    Més informació "New type 2 diabetes biomarker identified"

  • 22/12/2015 - Press release

    Using telemedicine to treat heart failure reduces clinical complications and decreases the cost by over 3500 euros per patient

    A study by the Cardiology Service's Heart Failure Unit at the Hospital del Mar and IMIM (Hospital del Mar Medical Research Institute) has demonstrated that patients with chronic heart failure (HF) who are telephonically monitored have better results with regard to relapse and rehospitalisation than patients that receive conventional on-site follow-up. For six months the researchers used an electronic platform to analyse the evolution of a group of telephonically monitored patients, who used videoconferencing to communicate with the healthcare team. According to the study published in the Journal of Telemedicine and Telecare, the group being monitored using telemedicine also involved a 3,546 euro reduction in average cost per patient compared to the control group, over the six months of follow-up.

    Més informació "Using telemedicine to treat heart failure reduces clinical complications and decreases the cost by over 3500 euros per patient"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact